cDC2s specialize in priming CD4+ T cells via antigen presentation on MHCII (Box 1), and are thus capable of efficiently polarizing tumour-infiltrating lymphocytes (TILs) toward anti-tumour T helper 1 (Th1) or Th17 phenotypes1,2. The gene discussed is CD4; the disease is neoplasm.